Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Fineline Cube Apr 28, 2026
Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Fineline Cube Apr 27, 2026
Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Fineline Cube Apr 27, 2026
Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study – First-in-Class Dual-Target Therapy for Hypertension and High LDL-C

Fineline Cube Apr 28, 2026
Company Drug

Hinova Pharmaceuticals Reports Positive Phase IIa Results for HP515 in MASH Treatment – First THR-β Agonist Candidate in China

Fineline Cube Apr 28, 2026
Company Deals R&D

Biogen and Tsinghua University Launch Three-Year Neuroscience Collaboration

Fineline Cube Jan 5, 2023

US-based Biogen (NASDAQ: BIIB) and the School of Pharmaceutical Sciences at Tsinghua University have announced...

Policy / Regulatory

China’s NHC and NATCM Launch Integrated Pain Management Pilot Plan

Fineline Cube Jan 5, 2023

The National Health Commission (NHC) and the National Administration of Traditional Chinese Medicine (NATCM) have...

Company Deals

Zhongchao Partners with Natco Pharma to Distribute Drugs in China

Fineline Cube Jan 5, 2023

Zhongchao Inc. (NASDAQ: ZCMD), a Shanghai-based online health education provider, has announced multiple agreements with...

Company Deals

By-Health to Establish Nutrition Research Center with Shanghai Institute

Fineline Cube Jan 5, 2023

China-based By-Health Co., Ltd. (SHE: 300146) is set to establish a “scientific nutrition research and...

Company Deals

CANbridge Secures Global Rights to Second-Generation Gene Therapy for SMA

Fineline Cube Jan 4, 2023

China – based biopharma CANbridge Pharmaceuticals Inc. (HKG: 1228) has unveiled a license deal to...

Company Drug

Transcenta’s TST003 Receives Clinical Trial Approval in China and US

Fineline Cube Jan 4, 2023

China – based biopharma Transcenta Holding Ltd (HKG: 6628) has announced that it has received...

Company Drug

Henlius’ Hanbeitai Gains NMPA Approval for Expanded Indications

Fineline Cube Jan 4, 2023

Shanghai Henlius Biotech Inc. (HKG: 2696) has announced that the National Medical Products Administration (NMPA)...

Company Deals

Sihuan’s Hui Sheng Bio Completes Series A+ Financing for Diabetes Pipeline

Fineline Cube Jan 4, 2023

China – based Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced the successful completion...

Company Drug

HutchMed Completes Enrollment for Phase III ESLIM-01 Study of Sovleplenib in ITP

Fineline Cube Jan 4, 2023

Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has announced the completion of patient enrollment...

Company Drug

RemeGen’s RC48 Gains NMPA Approval for Phase II Study in Bladder Cancer

Fineline Cube Jan 4, 2023

China – based biopharmaceutical company RemeGen Ltd (HKG: 9995) has announced that it has received...

Company Deals

Apeloa and Simcere Partner for CDMO Services and R&D Collaboration

Fineline Cube Jan 4, 2023

China – based contract development and manufacturing organization (CDMO) Apeloa Pharmaceutical Co., Ltd (SHE: 000739)...

Company Deals

Sino Biopharmaceutical’s CTTQ Partners with ProteLight for Antibacterial Peptide PL-5

Fineline Cube Jan 4, 2023

China – based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary Jiangsu Chia...

Company Deals

Inscinstech Raises RMB 150 Million in Series A+, B, and B+ Rounds

Fineline Cube Jan 4, 2023

Inscinstech Inc., a leading specialist in biological separation technology based in Suzhou, China, has successfully...

Company

Everest Medicines Outlines Strategic Plans for Expansion and Growth

Fineline Cube Jan 4, 2023

China – based biopharmaceutical company Everest Medicines (HKG: 1952) has announced its strategic plans for...

Company

Zai Lab Appoints Dr. Rafael Amado as President of Cancer R&D

Fineline Cube Jan 4, 2023

Chinese biopharmaceutical company Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has announced the appointment of...

Company Drug

Jiangxi Jemincare Gains FDA Approval for Clinical Trial of JYB1907 in Solid Tumors

Fineline Cube Jan 4, 2023

China – based Jiangxi Jemincare Group has announced that it has received approval from the...

Company Drug

Mabwell Receives NMPA Approval for Clinical Trial of 9MW3011 in Rare Diseases

Fineline Cube Jan 4, 2023

China – based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that it has...

Company Drug

Staidson’s Anti-C5a Monoclonal Antibody STSA-1002 Accepted for NMPA Review

Fineline Cube Jan 3, 2023

China-based Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204) has announced that the clinical trial filing...

Company Deals

Guangdong Raynovent Biotech Secures RMB 370 Million in Series C Financing

Fineline Cube Jan 3, 2023

Guangdong Raynovent Biotech Co., Ltd, a controlling subsidiary of China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd...

Company

Hengrui Pharmaceuticals Appoints Dr. Jiang Ningjun as Deputy General Manager and CSO

Fineline Cube Jan 3, 2023

China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced the appointment of Dr. “Frank” Jiang Ningjun...

Posts pagination

1 … 570 571 572 … 657

Recent updates

  • Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design
  • BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study – First-in-Class Dual-Target Therapy for Hypertension and High LDL-C
  • Hinova Pharmaceuticals Reports Positive Phase IIa Results for HP515 in MASH Treatment – First THR-β Agonist Candidate in China
  • Bio-Thera Solutions Reports 25.84% Revenue Growth in 2025 Driven by Biosimilar Portfolio Expansion and US Market Entry
  • Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Company Drug

BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study – First-in-Class Dual-Target Therapy for Hypertension and High LDL-C

Company Drug

Hinova Pharmaceuticals Reports Positive Phase IIa Results for HP515 in MASH Treatment – First THR-β Agonist Candidate in China

Others

Bio-Thera Solutions Reports 25.84% Revenue Growth in 2025 Driven by Biosimilar Portfolio Expansion and US Market Entry

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.